Europe Newborn Screening Market

The Europe newborn screening market was valued at US$ 328.04 million in 2022 and is expected to reach US$ 653.83 million by 2030; it is estimated to grow at a CAGR of 9.0% from 2022 to 2030.

Rising Burden of Congenital Diseases Fuels the Europe Newborn Screening Market.

Congenital diseases can lead to lifelong health challenges if not detected and managed early. These diseases can contribute to long-term disability, significantly affecting families, individuals, healthcare systems, and societies. The WHO estimates that 240,000 newborns worldwide succumb to death each year within 28 days of birth due to these diseases. An additional 170,000 children die between the age of 1 month and 5 years due to congenital diseases. A growing understanding of the genetic basis of many congenital diseases is one of the several factors contributing to the increasing burden of these conditions. Advancements in genomics and genetic testing have enabled healthcare providers to identify a broader range of genetic mutations and conditions in newborns. This expanded knowledge has highlighted the importance of early diagnosis through newborn screening to initiate timely interventions and treatments.

Changing demographics such as maternal age, environmental exposures, and altering lifestyle habits increase the risk of congenital conditions in newborns. Moreover, the number of births occurring every day is on the rise due to the burgeoning global population, resulting in an expanding pool of infants that can be at risk of congenital diseases. In addition, healthcare systems and policymakers recognize the long-term benefits of early disease detection. They increasingly incorporate newborn screening into routine healthcare protocols and insurance coverage, further stimulating market growth. The rising burden of congenital diseases is a significant driver behind the growth of the newborn screening market.

Europe Newborn Screening Market Overview

The European newborn screening market is segmented into Germany, the UK, France, Italy, Spain , and the Rest of Europe. Growth of the newborn screening market in Europe is driven by increased healthcare spending and an upsurge in the occurrence of congenital diseases, neonatal diseases, and other newborn diseases. Developments in techniques employed in medical research and several diagnostic screening procedures for the early detection of illnesses are also benefiting the market in Europe. The number of newborn screening programs across the region is expected to increase rapidly as government and nongovernment organizations are developing measures to enhance mother-childcare. According to information by NCBI in 2022, screening is anticipated to benefit ~4,000 children annually in the EU. The development of innovative diagnostic methods (such as MS/MS and molecular technologies), therapeutic options (such as gene therapy and enzyme replacement therapies), and increased understanding of rare diseases are driving the expansion of newborn screening programs.

Healthcare providers in European countries are offering comprehensive newborn screening panels, encompassing a broader spectrum of genetic and metabolic conditions. Healthcare authorities in several European countries have implemented mandatory newborn screening programs, ensuring every newborn undergoes essential screenings shortly after birth. As per a data published by NCBI in 2023, both spinal muscular atrophy and severe combined immunodeficiency (SCID) screening are evolving quickly; Norway, Germany, and other European countries had plans to include SMA screening in their national screening programs from 2021 and 2022 onward. Regional pilot programs are already underway in many other nations. SCID screening was just launched in the Czech Republic. This legislative support has increased the overall volume of screening tests and created a stable and predictable market for screening service providers.

Europe Newborn Screening Market Revenue and Forecast to 2030 (US$ Million)

Europe Newborn Screening Market Segmentation 

The Europe newborn screening market is segmented based on product type, technology, test type, end user, and country.

Based on product type, the Europe newborn screening market is bifurcated into reagents and assay kits, and instruments. The reagents and assay kits segment held a larger Europe newborn screening market share in 2022. The reagents and assay kits segment is subsegmented into DNA-based assays, and immunoassays and enzymatic assays. Instruments segment is subsegmented into newborn disorder screening instruments, pulse oximeters, newborn hearing screening instruments, and other instruments.

In terms of technology, the Europe newborn screening market is categorized into tandem mass spectrometry (TMS), molecular assays, immunoassays and enzymatic assay, pulse oximetry screening technology, and other technologies. The pulse oximetry screening technology segment held the largest Europe newborn screening market share in 2022.

Based on test type, the Europe newborn screening market is categorized into dry blood spot test, hearing screen test, critical congenital heart diseases (CCHD) test, and other test types. The dry blood spot test segment held the largest Europe newborn screening market share in 2022.

By end user, the Europe newborn screening market is segmented into hospitals and clinics and diagnostic laboratories. The hospitals and clinics segment held a larger Europe newborn screening market share in 2022.

By country, the Europe newborn screening market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. France dominated the Europe newborn screening market in 2022.

Bio-Rad Laboratories Inc, Masimo Corp, Medtronic Plc, MRC Holland BV, Natus Medical Inc, PerkinElmer Inc, Waters Corp, and Zentech SA are some of the leading companies operating in the Europe newborn screening market.

Europe Newborn Screening Strategic Insights

Strategic insights for the Europe Newborn Screening provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Newborn Screening Report Scope

Europe Newborn Screening Regional Insights

The geographic scope of the Europe Newborn Screening refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.